Symeon Missios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Symeon Missios has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Kimon Bekelis
Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon
2 shared publications - Clemens Maria Schirmer
Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA
1 shared publication - Daniel R. Calnan
Perelman School of Medicine at the University of Pennsylvania
1 shared publication - Javaad Ahmad
Population Health Research Institute of New York, Melville, NY (K.B., S.M., J.A., T.A.M.).
1 shared publication - Jonathan Skinner
Dartmouth College and NBER, United States of America
1 shared publication - Nicos Labropoulos
Division of Vascular Surgery, Stony Brook Medicine, Stony Brook, NY, USA
1 shared publication
Latest Publications
- 1 December 2020
- Published by Wolters Kluwer Health in Stroke
- Vol. 51 (12) , 3570-3576
Ischemic Stroke Occurs Less Frequently in Patients With COVID-19
Background and Purpose: The impact of coronavirus disease 2019 (COVID-19) on the occurrence of ischemic stroke has been the subject of increased speculation but has not been confirmed in large observational studies. We investigated the association between COVID-19 and stroke. Methods: We performed a cross-sectional study involving patients discharged from a healthcare system in New York State, from January to April 2020. A mixed-effects logistic regression analysis and a propensity score–weighted analysis were used to control for confounders and investigate the association of COVID-19 with ischemic stroke. Similar techniques were used to detect the impact of concurrent COVID-19 infection on unfavorable outcomes for patients with stroke. Results: Among 24 808 discharges, 2513 (10.1%) were diagnosed with COVID-19, and 566 (0.2%) presented with acute ischemic stroke. Patients diagnosed with COVID-19 were at one-quarter the odds of stroke compared with other patients (odds ratio, 0.25 [95% CI, 0.16–0.40]). This association was consistent in all age groups. Our results were robust in sensitivity analyses, including propensity score–weighted regression models. In patients presenting with stroke, concurrent infection with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was associated with higher case-fatality (odds ratio, 10.50 [95% CI, 3.54–31.18]) and a trend towards increased occurrence of discharge to rehabilitation (odds ratio, 2.45 [95% CI, 0.81–1.25]). Conclusions: Using a comprehensive cross-section of patients from a large NY-based healthcare system, we did not identify a positive association between ischemic stroke and COVID-19. However, patients with stroke with COVID-19 had worse outcomes compared with those without, with over a 9-fold increase in mortality. Although no definitive conclusions can be reached from our observational study, our data do not support the concerns for an epidemic of stroke in young adults with COVID-19.
- 1 December 2020
- Published by Wolters Kluwer Health in Stroke
- Vol. 51 (12) , 3570-3576
Ischemic Stroke Occurs Less Frequently in Patients With COVID-19
Background and Purpose: The impact of coronavirus disease 2019 (COVID-19) on the occurrence of ischemic stroke has been the subject of increased speculation but has not been confirmed in large observational studies. We investigated the association between COVID-19 and stroke. Methods: We performed a cross-sectional study involving patients discharged from a healthcare system in New York State, from January to April 2020. A mixed-effects logistic regression analysis and a propensity score–weighted analysis were used to control for confounders and investigate the association of COVID-19 with ischemic stroke. Similar techniques were used to detect the impact of concurrent COVID-19 infection on unfavorable outcomes for patients with stroke. Results: Among 24 808 discharges, 2513 (10.1%) were diagnosed with COVID-19, and 566 (0.2%) presented with acute ischemic stroke. Patients diagnosed with COVID-19 were at one-quarter the odds of stroke compared with other patients (odds ratio, 0.25 [95% CI, 0.16–0.40]). This association was consistent in all age groups. Our results were robust in sensitivity analyses, including propensity score–weighted regression models. In patients presenting with stroke, concurrent infection with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was associated with higher case-fatality (odds ratio, 10.50 [95% CI, 3.54–31.18]) and a trend towards increased occurrence of discharge to rehabilitation (odds ratio, 2.45 [95% CI, 0.81–1.25]). Conclusions: Using a comprehensive cross-section of patients from a large NY-based healthcare system, we did not identify a positive association between ischemic stroke and COVID-19. However, patients with stroke with COVID-19 had worse outcomes compared with those without, with over a 9-fold increase in mortality. Although no definitive conclusions can be reached from our observational study, our data do not support the concerns for an epidemic of stroke in young adults with COVID-19.
- Open Access
- 4 March 2015
- Published by Springer Nature in BMC Health Services Research
- Vol. 15 (1) , 1-8
Drivers of hospitalization cost after craniotomy for tumor resection: creation and validation of a predictive model
The economic sustainability of all areas of medicine is under scrutiny. Limited data exist on the drivers of cost after a craniotomy for tumor resection (CTR). The objective of the present study was to develop and validate a predictive model of hospitalization cost after CTR. We performed a retrospective study involving CTR patients who were registered in the Nationwide Inpatient Sample (NIS) database from 2005–2010. This cohort underwent 1:1 randomization to create derivation and validation subsamples. Regression techniques were used for the creation of a parsimonious predictive model. Of the 36,433 patients undergoing CTR, 14638 (40.2%) underwent craniotomies for primary malignant, 9574 (26.3%) for metastatic, and 11414 (31.3%) for benign tumors. The median hospitalization cost was $24,504 (Interquartile Range (IQR), $4,265-$44,743). Common drivers of cost identified in the multivariate analyses included: length of stay, number of procedures, hospital size and region, and patient income. The models were validated in independent cohorts and demonstrated final R2 very similar to the initial models. The predicted and observed values in the validation cohort demonstrated good correlation. This national study identified significant drivers of hospitalization cost after CTR. The presented model can be utilized as an adjunct in the cost containment debate and the creation of data-driven policies.
- 4 March 2015
- Published by Springer Nature in BMC Health Services Research
- Vol. 15 (1) , 1-8
Open AccessDrivers of hospitalization cost after craniotomy for tumor resection: creation and validation of a predictive model
The economic sustainability of all areas of medicine is under scrutiny. Limited data exist on the drivers of cost after a craniotomy for tumor resection (CTR). The objective of the present study was to develop and validate a predictive model of hospitalization cost after CTR. We performed a retrospective study involving CTR patients who were registered in the Nationwide Inpatient Sample (NIS) database from 2005–2010. This cohort underwent 1:1 randomization to create derivation and validation subsamples. Regression techniques were used for the creation of a parsimonious predictive model. Of the 36,433 patients undergoing CTR, 14638 (40.2%) underwent craniotomies for primary malignant, 9574 (26.3%) for metastatic, and 11414 (31.3%) for benign tumors. The median hospitalization cost was $24,504 (Interquartile Range (IQR), $4,265-$44,743). Common drivers of cost identified in the multivariate analyses included: length of stay, number of procedures, hospital size and region, and patient income. The models were validated in independent cohorts and demonstrated final R2 very similar to the initial models. The predicted and observed values in the validation cohort demonstrated good correlation. This national study identified significant drivers of hospitalization cost after CTR. The presented model can be utilized as an adjunct in the cost containment debate and the creation of data-driven policies.